Increased ventral striatal CB1 receptor binding is related to negative symptoms in drug-free patients with schizophrenia

NeuroImage

Volumn 79, Issue , 2013, Pages 304-312

  Ceccarini, Jenny ^a   De Hert, Marc ^b   Van Winkel, Ruud ^b,c   Peuskens, Joseph ^b   Bormans, Guy ^d   Kranaster, Laura ^e,f   Enning, Frank ^f   Koethe, Dagmar ^e,f   Leweke, F Markus ^e,f   Van Laere, Koen ^a,d  

^a DEPARTMENT OF IMAGING AND PATHOLOGY   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c MAASTRICHT UNIVERSITY   (Netherlands)

^d UNIVERSITY OF LEUVEN   (Belgium)

^e UNIVERSITY OF COLOGNE   (Germany)

^f UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Antipsychotics; Patients; PET; Psychotic symptoms; Schizophrenia; Type 1 cannabinoid receptor

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; CANNABINOID 1 RECEPTOR; CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; RADIOLIGAND; RISPERIDONE;

ADULT; ARTICLE; CADAVER; CINGULATE GYRUS; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; DRUG MECHANISM; FEMALE; FRONTAL CORTEX; HUMAN; IN VIVO STUDY; INSULA; LIMBIC CORTEX; MAJOR CLINICAL STUDY; MALE; NEGATIVE SYNDROME; NUCLEUS ACCUMBENS; PARIETAL LOBE; PATHOGENESIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECEPTOR BINDING; SCHIZOPHRENIA; SCORING SYSTEM; SYMPTOMATOLOGY; TEMPORAL LOBE;

ADULT; ANTIPSYCHOTIC AGENTS; BIOLOGICAL MARKERS; CORPUS STRIATUM; FEMALE; HUMANS; MALE; PYRIDINES; RADIOPHARMACEUTICALS; RECEPTOR, CANNABINOID, CB1; SCHIZOPHRENIA; STATISTICS AS TOPIC; TISSUE DISTRIBUTION;

EID: 84878363821     PISSN: 10538119     EISSN: 10959572     Source Type: Journal    
DOI: 10.1016/j.neuroimage.2013.04.052     Document Type: Article

References (55)

1. American Psychiatry Association Diagnostic and Statistical Manual of Mental Disorders 2000, American Psychiatry Association, Washington, DC. 4th ed., text rev.
2. Berding G., Schneider U., Gielow P., Buchert R., Donnerstag F., Brandau W., Knapp W.H., Emrich H.M., Muller-Vahl K. Feasibility of central cannabinoid CB1 receptor imaging with [124I]AM281 PET demonstrated in a schizophrenic patient. Psychiatry Res. 2006, 147:249-256.
3. Burns H.D., Van Laere K., Sanabria-Bohorquez S., Hamill T.G., Bormans G., Eng W.S., Gibson R., Ryan C., Connolly B., Patel S., Krause S., Vanko A., Van Hecken A., Dupont P., De Lepeleire I., Rothenberg P., Stoch S.A., Cote J., Hagmann W.K., Jewell J.P., Lin L.S., Liu P., Goulet M.T., Gottesdiener K., Wagner J.A., de Hoon J., Mortelmans L., Fong T.M., Hargreaves R.J. [18F]MK-9470, a positron emission tomography (PET) tracer for in vivo human PET brain imaging of the cannabinoid-1 receptor. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:9800-9805.
4. Chambers R.A., Krystal J.H., Self D.W. A neurobiological basis for substance abuse comorbidity in schizophrenia. Biol. Psychiatry 2001, 50:71-83.
5. Cornblatt B.A., Risch N.J., Faris G., Friedman D., Erlenmeyer-Kimling L. The Continuous Performance Test, identical pairs version (CPT-IP): I. New findings about sustained attention in normal families. Psychiatry Res. 1988, 26:223-238.
6. Coutts A.A., Anavi-Goffer S., Ross R.A., MacEwan D.J., Mackie K., Pertwee R.G., Irving A.J. Agonist-induced internalization and trafficking of cannabinoid CB1 receptors in hippocampal neurons. J. Neurosci. 2001, 21(7):2425-2433. (Apr 1).
7. Dalton V.S., Long L.E., Weickert C.S., Zavitsanou K. Paranoid schizophrenia is characterized by increased CB(1) receptor binding in the dorsolateral prefrontal cortex. Neuropsychopharmacology 2011, 36:1620-1630.
8. De Hert M., Wampers M., Jendricko T., Franic T., Vidovic D., De Vriendt N., Sweers K., Peuskens J., Van Winkel R. Effects of cannabis use on age at onset in schizophrenia and bipolar disorder. Schizophr. Res. 2011, 126:270-276.
9. Dean B., Sundram S., Bradbury R., Scarr E., Copolov D. Studies on [3H]CP-55940 binding in the human central nervous system: regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use. Neuroscience 2001, 103:9-15.
10. Di Chiara G., Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc. Natl. Acad. Sci. U. S. A. 1988, 85:5274-5278.
11. Eggan S.M., Lewis D.A. Immunocytochemical distribution of the cannabinoid CB1 receptor in the primate neocortex: a regional and laminar analysis. Cereb. Cortex 2007, 17:175-191.
12. Eggan S.M., Hashimoto T., Lewis D.A. Reduced cortical cannabinoid 1 receptor messenger RNA and protein expression in schizophrenia. Arch. Gen. Psychiatry 2008, 65:772-784.
13. Gérard N., Ceccarini J., Bormans G., Vanbilloen B., Casteels C., Goffin K., Bosier B., Lambert D.M., Van Laere K. Influence of chronic nicotine administration on cerebral type 1 cannabinoid receptor binding: an in vivo micro-PET study in the rat using [18F]MK-9470. J. Mol. Neurosci. 2010, 42:162-167.
14. Gérard N., Pieters G., Goffin K., Bormans G., Van Laere K. Brain type 1 cannabinoid receptor availability in patients with anorexia and bulimia nervosa. Biol. Psychiatry 2011, 70:777-784.
15. Giuffrida A., Leweke F.M., Gerth C.W., Schreiber D., Koethe D., Faulhaber J., Klosterkotter J., Piomelli D. Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms. Neuropsychopharmacology 2004, 29:2108-2114.
16. Guy W. Clinical Global Impression (CGI) 1976, 218-221. National Institute of Mental Health, Rockville MD.
17. Henquet C., Murray R., Linszen D., Van Os J. The environment and schizophrenia: the role of cannabis use. Schizophr. Bull. 2005, 31:608-612.
18. Hirvonen J., Goodwin R.S., Li C.T., Terry G.E., Zoghbi S.S., Morse C., Pike V.W., Volkow N.D., Huestis M.A., Innis R.B. Reversible and regionally selective downregulation of brain cannabinoid CB1 receptors in chronic daily cannabis smokers. Mol. Psychiatry 2012, 17:642-649.
19. Jenko K.J., Hirvonen J., Henter I.D., Anderson K.B., Zoghbi S.S., Hyde T.M., Deep-Soboslay A., Innis R.B., Kleinman J.E. Binding of a tritiated inverse agonist to cannabinoid CB1 receptors is increased in patients with schizophrenia. Schizophr. Res. 2012, 141:185-188.
20. Jones S.H., Thornicroft G., Coffey M., Dunn G. A brief mental health outcome scale-reliability and validity of the Global Assessment of Functioning (GAF). Br. J. Psychiatry 1995, 166:654-659.
21. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987, 13:261-276.
22. Kearn C.S., Blake-Palmer K., Daniel E., Mackie K., Glass M. Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors enhances heterodimer formation: a mechanism for receptor cross-talk?. Mol. Pharmacol. 2005, 67:1697-1704.
23. Koethe D., Llenos I.C., Dulay J.R., Hoyer C., Torrey E.F., Leweke F.M., Weis S. Expression of CB1 cannabinoid receptor in the anterior cingulate cortex in schizophrenia, bipolar disorder, and major depression. J. Neural Transm. 2007, 114:1055-1063.
24. Koethe D., Giuffrida A., Schreiber D., Hellmich M., Schultze-Lutter F., Ruhrmann S., Klosterkotter J., Piomelli D., Leweke F.M. Anandamide elevation in cerebrospinal fluid in initial prodromal states of psychosis. Br. J. Psychiatry 2009, 194:371-372.
25. Leweke F.M. Anandamide dysfunction in prodromal and established psychosis. Curr. Pharm. Des. 2012, 18:5188-5193.
26. Leweke F.M., Koethe D. Cannabis and psychiatric disorders: it is not only addiction. Addict. Biol. 2008, 13:264-275.
27. Leweke F.M., Giuffrida A., Wurster U., Emrich H.M., Piomelli D. Elevated endogenous cannabinoids in schizophrenia. Neuroreport 1999, 10:1665-1669.
28. Leweke F.M., Giuffrida A., Koethe D., Schreiber D., Nolden B.M., Kranaster L., Neatby M.A., Schneider M., Gerth C.W., Hellmich M., Klosterkotter J., Piomelli D. Anandamide levels in cerebrospinal fluid of first-episode schizophrenic patients: impact of cannabis use. Schizophr. Res. 2007, 94:29-36.
29. Leweke F.M., Piomelli D., Pahlisch F., Muhl D., Gerth C., Hoyer C., Klosterkotter J., Hellmich M., Koethe D. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl. Psychiatry 2012, 2:e94.
30. Llorca P.M., Blanc O., Samalin L., Bosia M., Cavallaro R. Factors involved in the level of functioning of patients with schizophrenia according to latent variable modeling. Eur. Psychiatry 2012, 27:396-400.
31. Meltzer H.Y., Arvanitis L., Bauer D., Rein W. Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder. Am. J. Psychiatry 2004, 161:975-984.
32. Moore T.H., Zammit S., Lingford-Hughes A., Barnes T.R., Jones P.B., Burke M., Lewis G. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 2007, 370:319-328.
33. Newell K.A., Deng C., Huang X.F. Increased cannabinoid receptor density in the posterior cingulate cortex in schizophrenia. Exp. Brain Res. 2006, 172:556-560.
34. Reitan R.M., Wolfson D. The Halstead-Reitan Neuropsychological Test Battery: Theory and Clinical Interpretation 1993, Neuropsychology Press, Tucson. second ed.
35. Rey A. L'Examen clinique en psychologie 1964.
36. Sanabria-Bohorquez S.M., Hamill T.G., Goffin K., De Lepeleire I., Bormans G., Burns H.D., Van Laere K. Kinetic analysis of the cannabinoid-1 receptor PET tracer [(18)F]MK-9470 in human brain. Eur. J. Nucl. Med. Mol. Imaging 2010, 37:920-933.
37. Solowij N., Stephens R.S., Roffman R.A., Babor T., Kadden R., Miller M., Christiansen K., McRee B., Vendetti J. Cognitive functioning of long-term heavy cannabis users seeking treatment. JAMA 2002, 287:1123-1131.
38. Soria G., Mendizabal V., Tourino C., Robledo P., Ledent C., Parmentier M., Maldonado R., Valverde O. Lack of CB1 cannabinoid receptor impairs cocaine self-administration. Neuropsychopharmacology 2005, 30:1670-1680.
39. Spreen O., Strauss E. A Compendium of Neuropsychological Tests: Administration, Norms, and Commentary 1998, Oxford University Press, New York. 2nd ed.
40. Terry G.E., Liow J.S., Zoghbi S.S., Hirvonen J., Farris A.G., Lerner A., Tauscher J.T., Schaus J.M., Phebus L., Felder C.C., Morse C.L., Hong J.S., Pike V.W., Halldin C., Innis R.B. Quantitation of cannabinoid CB1 receptors in healthy human brain using positron emission tomography and an inverse agonist radioligand. Neuroimage 2009, 48:362-370.
41. Thie J.A., Hubner K.F., Isidoro F.P., Smith G.T. A weight index for the standardized uptake value in 2-deoxy-2-[F-18]fluoro-D-glucose-positron emission tomography. Mol. Imaging Biol. 2007, 9:91-98.
42. Uriguen L., Garcia-Fuster M.J., Callado L.F., Morentin B., La H.R., Casado V., Lluis C., Franco R., Garcia-Sevilla J.A., Meana J.J. Immunodensity and mRNA expression of A2A adenosine, D2 dopamine, and CB1 cannabinoid receptors in postmortem frontal cortex of subjects with schizophrenia: effect of antipsychotic treatment. Psychopharmacology (Berl) 2009, 206:313-324.
43. Van Laere K., Nuttin B., Gabriels L., Dupont P., Rasmussen S., Greenberg B.D., Cosyns P. Metabolic imaging of anterior capsular stimulation in refractory obsessive-compulsive disorder: a key role for the subgenual anterior cingulate and ventral striatum. J. Nucl. Med. 2006, 47:740-747.
44. Van Laere K., Goffin K., Casteels C., Dupont P., Mortelmans L., de Hoon J., Bormans G. Gender-dependent increases with healthy aging of the human cerebral cannabinoid-type 1 receptor binding using [(18)F]MK-9470 PET. Neuroimage 2008, 39:1533-1541.
45. Van Laere K., Goffin K., Bormans G., Casteels C., Mortelmans L., de Hoon J., Grachev I., Vandenbulcke M., Pieters G. Relationship of type 1 cannabinoid receptor availability in the human brain to novelty-seeking temperament. Arch. Gen. Psychiatry 2009, 66:196-204.
46. Van Laere K., Casteels C., Dhollander I., Goffin K., Grachev I., Bormans G., Vandenberghe W. Widespread decrease of type 1 cannabinoid receptor availability in Huntington disease in vivo. J. Nucl. Med. 2010, 51:1413-1417.
47. Van Laere K., Casteels C., Lunskens S., Goffin K., Grachev I.D., Bormans G., Vandenberghe W. Regional changes in type 1 cannabinoid receptor availability in Parkinson's disease in vivo. Neurobiol. Aging 2012, 33:620.e1-620.e8.
48. Van Os J., Kapur S. Schizophrenia. Lancet 2009, 374:635-645.
49. Van Winkel R. Family-based analysis of genetic variation underlying psychosis-inducing effects of cannabis: sibling analysis and proband follow-up. Arch. Gen. Psychiatry 2011, 68:148-157. GROUP investigators.
50. Wallwork R.S., Fortgang R., Hashimoto R., Weinberger D.R., Dickinson D. Searching for a consensus five-factor model of the positive and negative syndrome scale for schizophrenia. Schizophr. Res. 2012, 137:246-250.
51. Wechsler D. Wechsler Adult Intelligence Scale 1974, Psychological Corporation, San Antonio. revised edn.
52. Wechsler D. WAIS-R Manual 1981, The Psychological Corporation, New York.
53. Wilson R.I., Nicoll R.A. Endocannabinoid signaling in the brain. Science 2002, 296:678-682.
54. Wong D.F., Kuwabara H., Horti A.G., Raymont V., Brasic J., Guevara M., Ye W., Dannals R.F., Ravert H.T., Nandi A., Rahmim A., Ming J.E., Grachev I., Roy C., Cascella N. Quantification of cerebral cannabinoid receptors subtype 1 (CB1) in healthy subjects and schizophrenia by the novel PET radioligand [11C]OMAR. Neuroimage 2010, 52:1505-1513.
55. 3H]SR141716A binding to cannabinoid CB1 receptors is increased in the anterior cingulate cortex in schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2004, 28:355-360.